Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00276315
Status:
COMPLETED
Last Update Posted:
2020-04-28
First Post:
2006-01-12
Brief Title:
Assessment of Effectiveness and Safety of Dysport for the Treatment of Hemifacial Spasm
Sponsor:
Ipsen
Organization:
Ipsen
Study Overview
Official Title:
A Phase III Multicentre Randomised Assessor-blind Parallel Groups Reference Drug Controlled Study to Assess the Efficacy and Safety of a Single Administration by Subcutaneous Injection of Dysport for the Treatment of Hemifacial Spasm
Status:
COMPLETED
Status Verified Date:
2020-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the effectiveness and safety of Dysport with the domestic Botulinum Toxin Type A manufactured by Lanzhou Biologic Product Institute PR China for the treatment of hemifacial spasm
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None